GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Short Interest

Stayble Therapeutics AB (OSTO:STABL) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Stayble Therapeutics AB's Short Interest

For the Biotechnology subindustry, Stayble Therapeutics AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Short Interest falls into.


Stayble Therapeutics AB (OSTO:STABL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Short Interest
Comparable Companies
OSTO:ACTI XSAT:HAMLET B OSTO:SPRINT OSTO:ISOFOL OSTO:ABLI OSTO:ELIC OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL OSTO:BIOWKS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
4K4:Germany
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Website
http://www.staybletherapeutics.com
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines